Skip to main content
Figure 6 | Journal of Immune Based Therapies and Vaccines

Figure 6

From: Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella

Figure 6

Recombinant E. coli vaccine vector delivering GFP antigen induced higher CTL response. Effector splenocytes of mice immunized with E. coli-GFP (GFP), our recombinant vaccine vector E. coli-GFP expressing invasin and hly (GFPinv), the recombinant vaccine vector also carrying the eukaryotic muIL12 vector (GFPinvIL12), or diluent control (PBS) were incubated with Raw/GFP target cells and assayed for cytotoxicity. Error bars represent quadruplicate wells. *GFPinvIL12 generated T cytotoxicity was significantly greater than GFP or PBS controls (p < 0.05).

Back to article page

Journal of Immune Based Therapies and Vaccines

ISSN: 1476-8518